/
Purpose and Mission Founded in 1992, Anika Therapeutics, Inc. ( Anika or Company ) is a global leader in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The Company leverages proprietary hyaluronic acid ( HA ) technology to develop highly differentiated products.
$15.07
$0.18 (-1.18%)
Live · 05:23 PM
The business is unprofitable at the operating level (-9.80% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 5.9% YoY. Margins deteriorated 5.5pp alongside, both lines moving the wrong way.
ROIC dropped from -1.91% to -4.99%, capital efficiency is deteriorating. Operating margin contracted 5.5pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$116M
▼ -5.9% YoY
Net Income (TTM)
-$11M
▲ +80.7% YoY
Op. Margin
-10.54%
▼ -5.5pp YoY
ROIC
-5.75%
▼ -3.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$1M
▲ +287.1% YoY
Op. Cash Flow (TTM)
$6M
▲ +107.1% YoY
Net Debt
-$41M
Net Cash Position
Cash & Equiv.
$67M
5Y CAGR: -2.9%
5Y CAGR: -17.5%
Continue Research
Anika Therapeutics (ANIK) trades above a two-stage DCF intrinsic value of about $4.36 per share, so at $15.07 the stock looks overvalued (71.0% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Anika Therapeutics scores 35/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $4.36 per share for ANIK, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $3.27. At today's $15.07, that puts the stock about 71.0% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Anika Therapeutics scores 35 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -10.5% operating margin and a -5.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. ANIK currently trades above its estimated intrinsic value and scores 35/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.